DrugPatentWatch Database Preview
Patents Expiring in October 2031
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi-aventis Us | ADLYXIN | lixisenatide | SOLUTION;SUBCUTANEOUS | 208471-002 | Jul 27, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ||||
Sanofi-aventis Us | ADLYXIN | lixisenatide | SOLUTION;SUBCUTANEOUS | 208471-001 | Jul 27, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ||||
Mannkind | AFREZZA | insulin recombinant human | POWDER;INHALATION | 022472-003 | Apr 17, 2015 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | METHOD OF CONTROLLING GLYCEMIA IN DIABETICS BY ADMINISTERING AN INITIAL DOSE OF INSULIN-FDKP WITH A MEAL; DETERMINING BLOOD GLUCOSE LEVEL 1-2 HRS AFTER AND ADMINISTERING A SUPPLEMENTAL DOSE OF INSULIN-FDKP IF POSTPRANDIAL GLUCOSE LEVEL IS >140 MG/DL | ||||
Mannkind | AFREZZA | insulin recombinant human | POWDER;INHALATION | 022472-002 | Jun 27, 2014 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | METHOD OF CONTROLLING GLYCEMIA IN DIABETICS BY ADMINISTERING AN INITIAL DOSE OF INSULIN-FDKP WITH A MEAL; DETERMINING BLOOD GLUCOSE LEVEL 1-2 HRS AFTER AND ADMINISTERING A SUPPLEMENTAL DOSE OF INSULIN-FDKP IF POSTPRANDIAL GLUCOSE LEVEL IS >140 MG/DL | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |